{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:29:26Z","timestamp":1793046566455,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.amjmed.2008.11.025","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T17:52:34Z","timestamp":1238435554000},"page":"322-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Renal Effects of Anti-angiogenesis Therapy: Update for the Internist"],"prefix":"10.1016","volume":"122","author":[{"given":"Faina","family":"Gurevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2008.11.025_bib1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2008.11.025_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2008.11.025_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J Mol Med"},{"issue":"2","key":"10.1016\/j.amjmed.2008.11.025_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2353\/ajpath.2006.050834","article-title":"Vascular endothelial growth factor localization in the adult","volume":"168","author":"Maharaj","year":"2006","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.amjmed.2008.11.025_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1083\/jcb.140.4.947","article-title":"Vascular endothelial growth factor induces endothelial fenestrations in vitro","volume":"140","author":"Esser","year":"1998","journal-title":"J Cell Biol"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2008.11.025_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.5-suppl_1-20","article-title":"Antiangiogenic strategies and agents in clinical trials","volume":"5","author":"Rosen","year":"2000","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.amjmed.2008.11.025_bib7","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.amjmed.2008.11.025_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor","volume":"288","author":"Lin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjmed.2008.11.025_bib9","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.11.025_bib10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.11.025_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.11.025_bib12","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.11.025_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2407-7-91","article-title":"Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study","volume":"7","author":"Emmanouilides","year":"2007","journal-title":"BMC Cancer"},{"issue":"47","key":"10.1016\/j.amjmed.2008.11.025_bib14","doi-asserted-by":"crossref","first-page":"18363","DOI":"10.1073\/pnas.0708865104","article-title":"VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade","volume":"104","author":"Rudge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.amjmed.2008.11.025_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2008.11.025_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2008.11.025_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/07853890510007205","article-title":"Acute renal failure in cancer patients","volume":"37","author":"Lameire","year":"2005","journal-title":"Ann Med"},{"issue":"14S","key":"10.1016\/j.amjmed.2008.11.025_bib18","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1200\/jco.2004.22.90140.3702","article-title":"Wound healing\/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab","volume":"22","author":"Hurwitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2008.11.025_bib21","first-page":"1","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in cancer patients","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib23","first-page":"H1054","article-title":"VEGF upregulates eNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib24","doi-asserted-by":"crossref","first-page":"33057","DOI":"10.1074\/jbc.274.46.33057","article-title":"Vascular endothelial growth factor governs nitric-oxide synthase expression via a KDR\/Flk-1 receptor and a protein kinase C signaling pathway","volume":"274","author":"Shen","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.amjmed.2008.11.025_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11906-999-0016-7","article-title":"Role of nitric oxide in the control of renal function and salt sensitivity","volume":"1","author":"Zou","year":"1999","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjmed.2008.11.025_bib26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.HYP.0000249510.20326.72","article-title":"Hypertension","volume":"48","author":"Feihl","year":"2006","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.amjmed.2008.11.025_bib27","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1097\/00004872-198812040-00055","article-title":"Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat","volume":"6","author":"Struyker-Boudier","year":"1988","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.amjmed.2008.11.025_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0026-2862(78)90070-5","article-title":"Arteriolar rarefaction in the conjunctiva of human essential hypertensives","volume":"16","author":"Harper","year":"1978","journal-title":"Microvasc Res"},{"key":"10.1016\/j.amjmed.2008.11.025_bib29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0024-3205(00)00693-7","article-title":"Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents","volume":"67","author":"Castilla","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.amjmed.2008.11.025_bib30","doi-asserted-by":"crossref","first-page":"H1395","DOI":"10.1152\/ajpheart.01277.2005","article-title":"Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2","volume":"291","author":"Gonzalez-Pacheco","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5B","key":"10.1016\/j.amjmed.2008.11.025_bib31","first-page":"3465","article-title":"Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab","volume":"27","author":"Pande","year":"2007","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.amjmed.2008.11.025_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.amjmed.2008.11.025_bib33","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2008.11.025_bib34","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjmed.2008.11.025_bib35","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2008.11.025_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2008.11.025_bib38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2008.11.025_bib39","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjmed.2008.11.025_bib40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"10.1016\/j.amjmed.2008.11.025_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.amjmed.2008.11.025_bib42","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","article-title":"Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis","volume":"69","author":"Hara","year":"2006","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.amjmed.2008.11.025_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1345\/aph.1H635","article-title":"Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma","volume":"41","author":"Barakat","year":"2007","journal-title":"Ann Pharmacother"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309000060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309000060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:50:20Z","timestamp":1757580620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934309000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0002934309000060"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2008.11.025","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Effects of Anti-angiogenesis Therapy: Update for the Internist","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2008.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}